Pliant Therapeutics, Inc.(PLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PLRX Pliant Therapeutics, Inc.

Market Closed 12-12 16:00:00 EST

1.23

-0.09

-6.82%

盘后1.24

+0.01+0.81%

16:19 EST

High1.33	Low1.23	Vol1.57M
Open1.33	D1 Closing1.32	Amplitude7.95%
Mkt Cap75.58M	Tradable Cap68.35M	Total Shares61.45M
T/O1.97M	T/O Rate2.82%	Tradable Shares55.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PLRX","market":"US","secType":"STK","nameCN":"Pliant Therapeutics, Inc.","latestPrice":1.23,"timestamp":1765573200000,"preClose":1.32,"halted":0,"volume":1568529,"hourTrading":{"tag":"盘后","latestPrice":1.24,"preClose":1.23,"latestTime":"16:19 EST","volume":1206,"amount":1495.38,"timestamp":1765574377496},"delay":0,"floatShares":55573062,"shares":61449385,"eps":-2.866764,"marketStatus":"Market Closed","change":-0.09,"latestTime":"12-12 16:00:00 EST","open":1.33,"high":1.33,"low":1.225,"amount":1969322.5184,"amplitude":0.079545,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.866764,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1591156800000,"exchange":"NASDAQ","adjPreClose":1.32,"preHourTrading":{"tag":"盘前","latestPrice":1.32,"preClose":1.32,"latestTime":"09:10 EST","volume":25,"amount":33.1500025,"timestamp":1765548657626},"postHourTrading":{"tag":"盘后","latestPrice":1.24,"preClose":1.23,"latestTime":"16:19 EST","volume":1206,"amount":1495.38,"timestamp":1765574377496},"volumeRatio":0.8399976735629641,"impliedVol":0.2541,"impliedVolPercentile":0.116},"requestUrl":"/m/hq/s/PLRX/tweets","defaultTab":"tweets","newsList":[{"id":"2590661073","title":"Pliant Therapeutics Inc - Terminates Cmo ÉRic Lefebvre Effective December 15 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590661073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590661073?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:42","pubTimestamp":1765230176,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE1BI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRX","BK4007"],"gpt_icon":0},{"id":"2590836643","title":"Pliant Therapeutics Announces Departure of Chief Medical Officer Éric Lefebvre","url":"https://stock-news.laohu8.com/highlight/detail?id=2590836643","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590836643?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:42","pubTimestamp":1765230148,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics Inc. has announced that Chief Medical Officer ric Lefebvre, M.D., will be leaving the company effective December 15, 2025. Dr. Lefebvre is expected to continue assisting the company as a consultant to support the transition of his responsibilities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL7sNhWD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLRX"],"gpt_icon":0},{"id":"2589983435","title":"Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2589983435","media":"Benzinga_recent_news","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589983435?lang=en_us&edition=fundamental","pubTime":"2025-12-05 02:53","pubTimestamp":1764874380,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics posts interim Phase 1 data showing antitumor activity and durable responses for PLN-101095 in ICI-refractory advanced cancer patients.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/04/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/04/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49217318/pliant-cancer-drug-boosts-responses-when-paired-with-mercks-blockbuster-keytruda-in-tough-to-treat-tumors","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49217318/pliant-cancer-drug-boosts-responses-when-paired-with-mercks-blockbuster-keytruda-in-tough-to-treat-tumors","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU1066053197.SGD","IE00B1BXHZ80.USD","BK4213","LU0265550946.USD","LU0234572021.USD","LU2361044865.SGD","SG9999001176.USD","LU1162221912.USD","IE00BSNM7G36.USD","LU2461242641.AUD","MRK","PLRX","LU0266013472.USD","LU0211331839.USD","SG9999013999.USD","LU1093756325.SGD","SG9999014567.USD","LU1116320901.HKD","IE00BN8TJ469.HKD","IE000M9KFDE8.USD","LU0320765646.SGD","IE00BFTCPJ56.SGD","SG9999015358.SGD","CR","BK4550","LU1934455277.USD","SG9999001176.SGD","LU1066051811.HKD","LU1066051498.USD","LU0203345920.USD","LU1093756168.USD","LU1989772923.USD","LU2324357040.USD","SG9999002232.USD","LU1037948897.HKD","LU2023250504.SGD","LU1983299246.USD","PR","LU0070302665.USD","LU1291159041.SGD","LU1035773651.USD","LU1066051225.USD","LU0058720904.USD","LU0965509101.SGD","BK4533","LU1989772840.SGD","LU1974910355.USD","LU0238689110.USD","LU0861579265.USD"],"gpt_icon":0},{"id":"2588488146","title":"BRIEF-Pliant Therapeutics Announces Interim Data From PLN-101095","url":"https://stock-news.laohu8.com/highlight/detail?id=2588488146","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588488146?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:39","pubTimestamp":1764851965,"startTime":"0","endTime":"0","summary":"BRIEF-Pliant Therapeutics Announces Interim Data From PLN-101095Dec 4 (Reuters) - Pliant Therapeutics Inc PLRX.O:PLIANT THERAPEUTICS ANNOUNCES INTERIM DATA FROM PLN-101095 IN PATIENTS WITH IMMUNE CHEC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA02B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRX","BK4007"],"gpt_icon":0},{"id":"2588881986","title":"Pliant Therapeutics Announces Interim Data From Pln-101095 in Patients With Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588881986?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:30","pubTimestamp":1764851420,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA02B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRX","BK4007"],"gpt_icon":0},{"id":"2588819998","title":"Pliant Therapeutics Inc: to Accelerate Development of Pln-101095 With Initiation of a Phase 1B Expansion Trial in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588819998","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588819998?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:30","pubTimestamp":1764851420,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA02B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PLRX"],"gpt_icon":0},{"id":"2588881609","title":"Pliant Therapeutics Reports Promising Interim Results for PLN-101095 in Refractory Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881609","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588881609?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:30","pubTimestamp":1764851420,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics Inc. has announced interim data from its Phase 1 dose escalation clinical trial evaluating PLN-101095, an oral, small molecule dual selective inhibitor of αvβ8 and αvβ1, in combination with pembrolizumab for patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors. The interim results include one complete response and three partial responses among heavily pretreated patients in high dose cohorts, with a median treatment duration of 15 months. The company plans to initiate a Phase 1b expansion trial in 2026. Final data from this trial will be presented at an upcoming scientific conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDLbkKTnY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","LU2095319765.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","PLRX","LU0314104364.USD","IE00B64PRP62.GBP","BK4588","NDAQ","IE00BGHQF748.EUR","BK4007","LU2210149790.SGD"],"gpt_icon":0},{"id":"2584926017","title":"Pliant Therapeutics Q3 Net Income USD -26.301 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926017","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926017?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:58","pubTimestamp":1763571483,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Pliant Therapeutics Q3 operating expenses USD -28.269 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202521:05:47.75 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDbPhXkD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLRX"],"gpt_icon":0},{"id":"2582875146","title":"Canaccord Genuity Keeps Their Hold Rating on Pliant Therapeutics (PLRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875146","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875146?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:18","pubTimestamp":1762777103,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Edward Nash maintained a Hold rating on Pliant Therapeutics today and set a price target of $4.00. According to TipRanks,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-keeps-their-hold-rating-on-pliant-therapeutics-plrx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-keeps-their-hold-rating-on-pliant-therapeutics-plrx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRX"],"gpt_icon":0},{"id":"2581000233","title":"RBC Capital Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000233","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000233?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:38","pubTimestamp":1762519087,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on Pliant Therapeutics, with a price target of $2.00. The ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-pliant-therapeutics-plrx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":"46fe14036bd3cdaf869148f08f7adcff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-pliant-therapeutics-plrx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRX"],"gpt_icon":0},{"id":"2581454440","title":"Pliant Therapeutics Q3 net loss narrows to $26.3 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581454440","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581454440?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:52","pubTimestamp":1762465936,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics Q3 net loss narrows to $26.3 mlnOverviewPliant Q3 net loss narrows to $26.3 mln, driven by BEACON-IPF discontinuationCompany completed voluntary prepayment of Oxford Finance loanOu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1JK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRX","BK4007"],"gpt_icon":0},{"id":"2581010986","title":"Pliant Therapeutics reports third quarter net loss of $26.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581010986","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581010986?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:13","pubTimestamp":1762463605,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics Inc. reported a net loss of $26.3 million for the third quarter of 2025, compared to a net loss of $57.8 million in the same period last year. Research and development expenses were $17.9 million, down from $47.8 million, primarily due to the discontinuation of the BEACON-IPF program. General and administrative expenses decreased to $10.3 million from $14.3 million, mainly due to lower personnel-related costs following a strategic workforce restructuring. As of September 30, 2025, the company had $243.3 million in cash, cash equivalents, and short-term investments. Key business developments include the completion of enrollment in the Phase 1 trial of PLN-101095 in solid tumors and the winding down of BEACON-IPF activities, with close out expected in the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL10Q7m0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","PLRX","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4585","BK4007","BK4112","LU2095319765.USD"],"gpt_icon":0},{"id":"2580294246","title":"Pliant Therapeutics Inc  expected to post a loss of 52 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580294246","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580294246?lang=en_us&edition=fundamental","pubTime":"2025-11-03 19:33","pubTimestamp":1762169625,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics Inc  expected to post a loss of52cents a share - Earnings Preview Pliant Therapeutics Inc PLRX.OQ PLRX.O is expected to  show no change in quarterly revenue when it reports  result","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF0R2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRX","BK4007"],"gpt_icon":0},{"id":"2578528285","title":"Pliant Therapeutics Announces CBO Hans Hull’s Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2578528285","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578528285?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:59","pubTimestamp":1761339599,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics ( ($PLRX) ) just unveiled an announcement. On October 20, 2025, Pliant Therapeutics, Inc. announced the resignation of Hans Hul...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pliant-therapeutics-announces-cbo-hans-hulls-resignation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pliant-therapeutics-announces-cbo-hans-hulls-resignation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4139","PLRX","BK4007"],"gpt_icon":0},{"id":"2578754017","title":"Pliant Therapeutics Chief Business Officer Hans Hull Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2578754017","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578754017?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:33","pubTimestamp":1761337989,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics Inc. announced that Hans Hull has resigned as Chief Business Officer, effective October 20, 2025. The company stated that his resignation was not due to any disagreement related to company operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDLY1kV1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLRX"],"gpt_icon":0},{"id":"2577804894","title":"Pliant Therapeutics Completes $32.4 Million Voluntary Debt Prepayment, Fully Repays Loan Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2577804894","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577804894?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:44","pubTimestamp":1761000261,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics Inc. has announced the voluntary prepayment of $32.4 million, covering all outstanding principal, accrued interest, fees, and expenses under its Amended and Restated Loan and Security Agreement with Oxford Finance LLC and associated lenders. With this payment, all obligations and liabilities under the agreement have been fully satisfied and discharged, resulting in the termination of the loan agreement and related documents.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 20, 2025, and is s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL6zhcG7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLRX"],"gpt_icon":0},{"id":"2577489167","title":"Pliant Therapeutics Settles Loan with Oxford Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2577489167","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577489167?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:11","pubTimestamp":1760998304,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics ( ($PLRX) ) has provided an announcement. On October 14, 2025, Pliant Therapeutics, Inc. completed a voluntary prepayment of $3...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pliant-therapeutics-settles-loan-with-oxford-finance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pliant-therapeutics-settles-loan-with-oxford-finance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","PLRX","OXM","BK4202","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2574147452","title":"U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity","url":"https://stock-news.laohu8.com/highlight/detail?id=2574147452","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574147452?lang=en_us&edition=fundamental","pubTime":"2025-10-10 15:16","pubTimestamp":1760080574,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, DoximityOct 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Beacon ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nL5N3VR08D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","BBT","RSG","NEM","BEAM","DVN","PEP","XRAY","CDTX","LU0868494617.USD","BTU","ZBH","ALGM","ALLO","LU1629891620.HKD","SSRM","PODD","GMED","HSII","MCHP","ZYME","LU0466842654.USD","ALGN","INSP","RGLD","TSYW.SI","MPWR","OCFC","PLRX","BK4588","ABBV","BK4017","JNJ","FANG","HL","NRIX","CABA","COLB","WM","TXN","DOCS","CMA","CNR","KIDS","IE00B2B36J28.USD","LSCC"],"gpt_icon":1},{"id":"2574146828","title":"Pliant Therapeutics Inc : JP Morgan Cuts to Underweight From Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2574146828","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574146828?lang=en_us&edition=fundamental","pubTime":"2025-10-10 12:45","pubTimestamp":1760071518,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VR0PB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PLRX"],"gpt_icon":0},{"id":"2557146825","title":"Pliant Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2557146825","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557146825?lang=en_us&edition=fundamental","pubTime":"2025-08-08 12:08","pubTimestamp":1754626083,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryPliant Therapeutics Inc PLRX.OQ reported a quarterly adjusted loss of 71 cents per share for the quarter ended J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U00K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://pliantrx.com","stockEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":-0.3167},{"period":"3month","weight":-0.2264},{"period":"6month","weight":-0.1087},{"period":"1year","weight":-0.9112},{"period":"ytd","weight":-0.9066}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.114112},{"month":2,"riseRate":0.2,"avgChangeRate":-0.155174},{"month":3,"riseRate":0.2,"avgChangeRate":-0.172741},{"month":4,"riseRate":0.4,"avgChangeRate":-0.055837},{"month":5,"riseRate":0.2,"avgChangeRate":-0.100198},{"month":6,"riseRate":0.2,"avgChangeRate":-0.005064},{"month":7,"riseRate":0.5,"avgChangeRate":0.192342},{"month":8,"riseRate":0.5,"avgChangeRate":0.015165},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.05288},{"month":10,"riseRate":0.5,"avgChangeRate":0.054175},{"month":11,"riseRate":0.166667,"avgChangeRate":-0.035324},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.024758}],"exchange":"NASDAQ","name":"Pliant Therapeutics, Inc.","nameEN":"Pliant Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pliant Therapeutics, Inc.(PLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pliant Therapeutics, Inc.(PLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pliant Therapeutics, Inc.,PLRX,Pliant Therapeutics, Inc.股票,Pliant Therapeutics, Inc.股票老虎,Pliant Therapeutics, Inc.股票老虎国际,Pliant Therapeutics, Inc.行情,Pliant Therapeutics, Inc.股票行情,Pliant Therapeutics, Inc.股价,Pliant Therapeutics, Inc.股市,Pliant Therapeutics, Inc.股票价格,Pliant Therapeutics, Inc.股票交易,Pliant Therapeutics, Inc.股票购买,Pliant Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pliant Therapeutics, Inc.(PLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pliant Therapeutics, Inc.(PLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}